Silence Therapeutics (SLN) Cash & Equivalents: 2019-2025
Historic Cash & Equivalents for Silence Therapeutics (SLN) over the last 7 years, with Sep 2025 value amounting to $102.2 million.
- Silence Therapeutics' Cash & Equivalents rose 26.96% to $102.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.2 million, marking a year-over-year increase of 26.96%. This contributed to the annual value of $121.3 million for FY2024, which is 76.38% up from last year.
- Per Silence Therapeutics' latest filing, its Cash & Equivalents stood at $102.2 million for Q3 2025, which was down 10.51% from $114.2 million recorded in Q2 2025.
- Silence Therapeutics' 5-year Cash & Equivalents high stood at $143.4 million for Q1 2024, and its period low was $37.2 million during Q2 2023.
- For the 3-year period, Silence Therapeutics' Cash & Equivalents averaged around $97.6 million, with its median value being $102.2 million (2025).
- Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 676.88% in 2021, then tumbled by 42.73% in 2023.
- MRQ analysis of 5 years shows Silence Therapeutics' Cash & Equivalents stood at $99.1 million in 2021, then crashed by 35.14% to $64.3 million in 2022, then increased by 6.99% to $68.8 million in 2023, then skyrocketed by 76.38% to $121.3 million in 2024, then dropped by 15.77% to $102.2 million in 2025.
- Its Cash & Equivalents stands at $102.2 million for Q3 2025, versus $114.2 million for Q2 2025 and $136.5 million for Q1 2025.